Navigation Links
FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Date:3/28/2011

DUBLIN, Calif., March 28, 2011 /PRNewswire/ -- Carl Zeiss Meditec, Inc. announced today that the MEL 80™ Excimer Laser has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the treatment of hyperopia. This new indication complements the existing FDA approved applications of the surgical laser for myopia and astigmatism.  

"The MEL 80 combines premium optics with advanced excimer laser technology," said Ludwin Monz, president and chief executive officer of Carl Zeiss Meditec AG. "Adding the hyperopia indication enables us to offer a complete range of treatment options to meet the demands of refractive surgeons and their patients."  

More commonly known as farsightedness, hyperopia makes it difficult for a patient to focus on near objects. "Hyperopia has always been a more difficult problem to treat with laser surgery," said Dr. Jon Dishler of Greenwood Village, CO. "Now with the MEL 80, the task is easier and more precise.  Going forward, I would not attempt LASIK on my hyperopic patients without the MEL 80."

Clinical ResultsThe MEL 80 study for hyperopia included 189 patients age 22 to 69 years old, with a mean age of 47 years. A total of 369 eyes were treated. After 12 months, 148 patients, or 96.7 percent, showed uncorrected visual acuity of 20/40 or better.  The results of the study were presented at the annual meeting of the American Society of Cataract and Refractive Surgery in San Diego on March 27.

FDA IndicationThe MEL 80 Excimer Laser is indicated for use in primary Laser Assisted in situ Keratomileusis (LASIK) treatments for the reduction or elimination of naturally occurring hyperopia of less than or equal to +5.0 D with or without refractive astigmatism of > +0.5 D and < +3.0 D, with a maximum MRSE of +5.0 D, in patients who are 21 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by change in sphere and cylinder of < 0.5 D.

Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology suppliers. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. In the 2009/2010 (30 September) financial year, around 2,200 employees generated revenue of EUR 676 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. In financial year 2009/2010, the Group generated revenue of around EUR 2.98 billion. From financial year 2010/2011 onwards, eyeglass lens manufacturer Carl Zeiss Vision shall be integrated as an autonomous business group (revenue of around EUR 880 million in financial year 2009/2010). The Carl Zeiss Group thus employs a workforce of around 24,000 worldwide, more than 10,000 of whom are based in Germany. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For further information see: http://www.meditec.zeiss.comContact:Eva Sesselmann

Director Group Communications

Carl Zeiss Meditec AG

Goeschwitzer StraBe 51-52

07745 Jena

Telefon: +49 3641 220-331

Telefax: +49 3641 220-332

E-Mail: press@meditec.zeiss.comJackie Ferreira

Sr. Director, Marketing Communications

Carl Zeiss Meditec, Inc.

5160 Hacienda Dr.

Dublin, CA 94568

Phone : +1 925 557 4488

Fax:
+1 925 557 4615

E-Mail: j.ferreira@meditec.zeiss.com
'/>"/>

SOURCE Carl Zeiss Meditec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition ... - 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics ... the growing market of deep learning solutions within the healthcare domain. ... emerged as a novel solution to generate relevant insights from medical ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... March 23, 2017  Mirabilis Medical, a ... technology for non-invasive surgery, announced today CE Mark ... treatment of uterine fibroids throughout the European Union.  ... approval from the US Food and Drug Administration ... System in the United States.  The Mirabilis System ...
Breaking Medicine Technology:
(Date:3/25/2017)... Kennett Square, PA (PRWEB) , ... March 25, 2017 , ... ... one priority as a public relations partner. , All through the year, Garden ... stories and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
Breaking Medicine News(10 mins):